Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2015, Article ID 168935, 10 pages
http://dx.doi.org/10.1155/2015/168935
Review Article

Development of Monoclonal Antibodies in China: Overview and Prospects

State Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, Macau

Received 2 November 2014; Accepted 12 February 2015

Academic Editor: Michael Hust

Copyright © 2015 Mao-Yu Zhang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. N. Buss and S. Henderson, “Monoclonal antibody therapeutics: history and future,” Current Opinion in Pharmacology, vol. 12, pp. 615–622, 2012. View at Google Scholar
  2. J. H. Chon and G. Zarbis-Papastoitsis, “Advances in the production and downstream processing of antibodies,” New Biotechnology, vol. 28, no. 5, pp. 458–463, 2011. View at Publisher · View at Google Scholar · View at Scopus
  3. G. Kohler and C. Milstein, “Continuous cultures of fused cells secreting antibody of predefined specificity,” Nature, vol. 256, no. 5517, pp. 495–497, 1975. View at Publisher · View at Google Scholar · View at Scopus
  4. R. J. Ober, C. G. Radu, V. Ghetie, and E. S. Ward, “Differences in promiscuity for antibody-FcRn interactions across species: implications for therapeutic antibodies,” International Immunology, vol. 13, no. 12, pp. 1551–1559, 2001. View at Publisher · View at Google Scholar · View at Scopus
  5. W. Y. K. Hwang and J. Foote, “Immunogenicity of engineered antibodies,” Methods, vol. 36, no. 1, pp. 3–10, 2005. View at Publisher · View at Google Scholar · View at Scopus
  6. J. M. Reichert, “Monoclonal antibodies as innovative therapeutics,” Current Pharmaceutical Biotechnology, vol. 9, no. 6, pp. 423–430, 2008. View at Publisher · View at Google Scholar · View at Scopus
  7. S. L. Morrison, M. J. Johnson, L. A. Herzenberg, and V. T. Oi, “Chimeric human antibody molecules: mouse antigen-binding domains with human constant region domains,” Proceedings of the National Academy of Sciences of the United States of America, vol. 81, no. 21, pp. 6851–6855, 1984. View at Publisher · View at Google Scholar · View at Scopus
  8. M. Verhoeyen, C. Milstein, and G. Winter, “Reshaping human antibodies: grafting an antilysozyme activity,” Science, vol. 239, no. 4847, pp. 1534–1536, 1988. View at Publisher · View at Google Scholar · View at Scopus
  9. C. F. Barbas III, A. S. Kang, R. A. Lerner, and S. J. Benkovic, “Assembly of combinatorial antibody libraries on phage surfaces: the gene III site,” Proceedings of the National Academy of Sciences of the United States of America, vol. 88, no. 18, pp. 7978–7982, 1991. View at Publisher · View at Google Scholar · View at Scopus
  10. F. Breitling, S. Dubel, T. Seehaus, I. Klewinghaus, and M. Little, “A surface expression vector for antibody screening,” Gene, vol. 104, no. 2, pp. 147–153, 1991. View at Publisher · View at Google Scholar · View at Scopus
  11. H. R. Hoogenboom and G. Winter, “By-passing immunisation: human antibodies from synthetic repertoires of germline VH gene segments rearranged in vitro,” Journal of Molecular Biology, vol. 227, no. 2, pp. 381–388, 1992. View at Publisher · View at Google Scholar · View at Scopus
  12. A. Jakobovits, “Production of fully human antibodies by transgenic mice,” Current Opinion in Biotechnology, vol. 6, no. 5, pp. 561–566, 1995. View at Publisher · View at Google Scholar · View at Scopus
  13. D. M. Fishwild, S. L. O'Donnell, T. Bengoechea et al., “High-avidity human IgGκ monoclonal antibodies from a novel strain of minilocus transgenic mice,” Nature Biotechnology, vol. 14, no. 7, pp. 845–851, 1996. View at Publisher · View at Google Scholar · View at Scopus
  14. A. L. Nelson, E. Dhimolea, and J. M. Reichert, “Development trends for human monoclonal antibody therapeutics,” Nature Reviews Drug Discovery, vol. 9, no. 10, pp. 767–774, 2010. View at Publisher · View at Google Scholar · View at Scopus
  15. Z. Chen and J. Jiang, “Monoclonal antibody—from murine to humanized,” Foreign Medical Science, vol. 23, pp. 188–189, 2000. View at Google Scholar
  16. Y. Wang, W. Wu, Q. Li, and M. Gao, “The research progress and trend of biotech drugs in reseach years in China,” Pharmaceutical Biotechnology, vol. 20, pp. 1–11, 2013. View at Google Scholar
  17. H. Shi, M. Chen, and Y. Shi, “Challenges and prospects for monoclonal antibodies in China,” Journal of Commercial Biotechnology, vol. 19, pp. 48–54, 2013. View at Google Scholar
  18. X. C. Liao, “Early development of antibody therapeutics: key aspects of advancing an antibody drug from research to clinic,” Trends in Bio/Pharmaceutical Industry, vol. 5, pp. 18–23, 2009. View at Google Scholar
  19. T. Zhang, W. Chen, D. Pu, J. Zhang, and M. Wang, “The development and trend of antibody drugs,” Chinese Journal of New Drugs, vol. 17, no. 9, pp. 713–718, 2008. View at Google Scholar · View at Scopus
  20. M. D. Pescovitz, “Rituximab, an anti-CD20 monoclonal antibody: history and mechanism of action,” The American Journal of Transplantation, vol. 6, no. 5 I, pp. 859–866, 2006. View at Publisher · View at Google Scholar · View at Scopus
  21. G. P. Adams and L. M. Weiner, “Monoclonal antibody therapy of cancer,” Nature Biotechnology, vol. 23, no. 9, pp. 1147–1157, 2005. View at Publisher · View at Google Scholar · View at Scopus
  22. M. R. Smith, “Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance,” Oncogene, vol. 22, no. 47, pp. 7359–7368, 2003. View at Publisher · View at Google Scholar · View at Scopus
  23. A. Moeller and F. Emling, “Monoclonal antibodies against human tumor necrosis factor (TNF), and use there of,” 5231024, 1993.
  24. M. Allez, S. Vermeire, N. Mozziconacci et al., “The efficacy and safety of a third anti-TNF monoclonal antibody in Crohn's disease after failure of two other anti-TNF antibodies,” Alimentary Pharmacology and Therapeutics, vol. 31, no. 1, pp. 92–101, 2010. View at Publisher · View at Google Scholar · View at Scopus
  25. K. Kanai, S. Kuwabara, S. Misawa, and T. Hattori, “Failure of treatment with anti-VEGF monoclonal antibody for long-standing POEMS syndrome,” Internal Medicine, vol. 46, no. 6, pp. 311–313, 2007. View at Publisher · View at Google Scholar · View at Scopus
  26. N. Ferrara, K. J. Hillan, and W. Novotny, “Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy,” Biochemical and Biophysical Research Communications, vol. 333, no. 2, pp. 328–335, 2005. View at Publisher · View at Google Scholar · View at Scopus
  27. J. Mordenti, K. Thomsen, V. Licko, H. Chen, Y. G. Meng, and N. Ferrara, “Efficacy and concentration-response of murine anti-VEGF monoclonal antibody in tumor-bearing mice and extrapolation to humans,” Toxicologic Pathology, vol. 27, no. 1, pp. 14–21, 1999. View at Publisher · View at Google Scholar · View at Scopus
  28. J. Baselga, J. Cortés, S.-B. Kim et al., “Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer,” The New England Journal of Medicine, vol. 366, no. 2, pp. 109–119, 2012. View at Publisher · View at Google Scholar · View at Scopus
  29. J. M. Reichert, “Antibodies to watch in 2014: mid-year update,” MAbs, vol. 6, no. 4, pp. 799–802, 2014. View at Publisher · View at Google Scholar
  30. T. M. Brand, M. Iida, and D. L. Wheeler, “Molecular mechanisms of resistance to the EGFR monoclonal antibody cetuximab,” Cancer Biology and Therapy, vol. 11, no. 9, pp. 777–792, 2011. View at Publisher · View at Google Scholar · View at Scopus
  31. R. L. Ferris, E. M. Jaffee, and S. Ferrone, “Tumor antigen-targeted, monoclonal antibody-based immunotherapy: clinical response, cellular immunity, and immunoescape,” Journal of Clinical Oncology, vol. 28, no. 28, pp. 4390–4399, 2010. View at Publisher · View at Google Scholar · View at Scopus
  32. M. Gu and X. Zhao, “Monoclonal antibodies—focus point of anti-tumor drugs research,” China Cancer, vol. 12, pp. 523–525, 2003. View at Google Scholar
  33. G.-H. Gao, J. Li, H.-W. Xie, and Z. Lü, “Therapeutic effect of infliximab on moderate and severe active rheumatoid arthriti,” Journal of Southern Medical University, vol. 30, no. 4, pp. 724–726, 2010. View at Google Scholar · View at Scopus
  34. W.-J. Sheng, B.-Y. Shang, Q.-F. Miao, and Y.-S. Zhen, “Construction of a single-chain Fv antibody against epidermal growth factor receptor and its antitumor activity,” Chinese Pharmaceutical Journal, vol. 46, no. 18, pp. 1393–1398, 2011. View at Google Scholar · View at Scopus
  35. J. M. Reichert, “Which are the antibodies to watch in 2013?” MAbs, vol. 5, no. 1, pp. 1–4, 2013. View at Publisher · View at Google Scholar · View at Scopus
  36. J. Tang, “Opportunities and challenges brought by monoclonal antibodies rapid development to biopharmaceutical in China,” Science and Technlogy Information, vol. 19, pp. 247–248, 2010. View at Google Scholar
  37. Z. Zhu, S. Chakraborti, Y. He et al., “Potent cross-reactive neutralization of SARS coronavirus isolates by human monoclonal antibodies,” Proceedings of the National Academy of Sciences of the United States of America, vol. 104, no. 29, pp. 12123–12128, 2007. View at Publisher · View at Google Scholar · View at Scopus
  38. P. Gagnon, “Monoclonal antibody purification with hydroxyapatite,” New Biotechnology, vol. 25, no. 5, pp. 287–293, 2009. View at Publisher · View at Google Scholar · View at Scopus
  39. J. Li, T. Sai, M. Berger et al., “Human antibodies for immunotherapy development generated via a human B cell hybridoma technology,” Proceedings of the National Academy of Sciences of the United States of America, vol. 103, no. 10, pp. 3557–3562, 2006. View at Publisher · View at Google Scholar · View at Scopus
  40. S. Kozlowski and P. Swann, “Current and future issues in the manufacturing and development of monoclonal antibodies,” Advanced Drug Delivery Reviews, vol. 58, no. 5-6, pp. 707–722, 2006. View at Publisher · View at Google Scholar · View at Scopus
  41. J. Ni, “New technologies for the generation of human monoclonal antibody,” Trends in Bio/Pharmaceutical Industry, vol. 5, no. 3, pp. 3–14, 2009. View at Google Scholar
  42. Z. Chen, “Biopharmaceutical industrialization prospect in China based on the antibodies,” Chinese Medicinal Biotechnology, vol. 2, pp. 2–5, 2007. View at Google Scholar
  43. C. Chen, “Challenges and opportunities of monoclonal antibody manufacturing in China,” Trends in Bio/Pharmaceutical Industry, vol. 5, pp. 28–33, 2009. View at Google Scholar
  44. D. Ju, “Development of antibody drugs in China,” Trends in Bio/Pharmaceutical Industry, vol. 5, pp. 34–39, 2009. View at Google Scholar
  45. X.-D. Yang, J. R. F. Corvalan, P. Wang, C. M.-N. Roy, and C. G. Davis, “Fully human anti-interleukin-8 monoclonal antibodies: potential therapeutics for the treatment of inflammatory disease states,” Journal of Leukocyte Biology, vol. 66, no. 3, pp. 401–410, 1999. View at Google Scholar · View at Scopus
  46. X.-D. Yang, X.-C. Jia, J. R. F. Corvalan, P. Wang, and C. G. Davis, “Development of ABX-EGF, a fully human anti-EGF receptor monoclonal antibody, for cancer therapy,” Critical Reviews in Oncology/Hematology, vol. 38, no. 1, pp. 17–23, 2001. View at Publisher · View at Google Scholar · View at Scopus
  47. J. Higbee and H. Tu, “Biosimilars: challenges and promises cabs workshop on biosimilar therapeutics,” Trends in Bio/Pharmaceutical Industry, vol. 5, pp. 42–44, 2009. View at Google Scholar
  48. S. Chhatre, C. Jones, R. Francis et al., “The integrated simulation and assessment of the impacts of process change in biotherapeutic antibody production,” Biotechnology Progress, vol. 22, no. 6, pp. 1612–1620, 2006. View at Publisher · View at Google Scholar · View at Scopus
  49. A. Beck and J. M. Reichert, “Approval of the first biosimilar antibodies in Europe: a major landmark for the biopharmaceutical industry,” mAbs, vol. 5, no. 5, pp. 621–623, 2013. View at Publisher · View at Google Scholar · View at Scopus
  50. K. J. Morrow Jr., “Advances in antibody manufacturing using mammalian cells,” Biotechnology Annual Review, vol. 13, pp. 95–113, 2007. View at Publisher · View at Google Scholar · View at Scopus
  51. B. Liu, “The progress of therapeutic antibody drug and the industrial key-technology of antibody production,” China Biotechnoloty, vol. 33, pp. 132–138, 2013. View at Google Scholar
  52. S. Cui and L. Tian, “Contrastive analysis of technology patent situation between China and US,” China Medical Biotechnology, vol. 7, pp. 389–395, 2012. View at Google Scholar
  53. G. Yu, “The SWOT analysis of antibody therapeutics in China,” Trends in Bio/Pharmaceutical Industry, vol. 5, pp. 24–27, 2009. View at Google Scholar
  54. L.-B. Zhou, H.-M. Yuan, S.-J. Yang, D. Xing, and F.-Y. Guo, “General situation and analysis of patent applications of monoclonal antibody in China,” Chinese Journal of New Drugs, vol. 22, no. 8, pp. 873–877, 2013. View at Google Scholar · View at Scopus